Laurus Labs Limited
LAURUSLABS.NS
INR1 003.50 -2.20%
Exchange: NSE | Sector: Healthcare | Industry: Drug Manufacturers Specialty Generic
Q1 2026
Published: Jun 30, 2025

Earnings Highlights

  • Revenue of $15.70B up 9% year-over-year
  • EPS of $3.02 increased by 115.7% from previous year
  • Gross margin of 59.4%
  • Net income of 1.63B
  • ""Despite pricing pressures from generic competitors, our focus on higher-margin products allows us to sustain profitability and drive future growth."" - Management Team
LAURUSLABS.NS
Laurus Labs Limited

Executive Summary

Laurus Labs Limited reported a remarkable performance for Q1 2026, showcasing a 9.02% YoY increase in revenue to ₹15,695.7 million, and a staggering 115.61% Year-over-Year (YoY) jump in net income, which reached ₹1,630.2 million. Key drivers of this growth included increases in both operational efficiency and cost-management strategies. The gross profit margin also improved significantly, reflecting successful adaptations to market dynamics and operational adjustments.

Management highlighted the company's commitment to innovation within its core segments, particularly in API production and contract pharmaceutical services. With a strategic focus on expanding its API portfolio and enhancing manufacturing capabilities, Laurus Labs positions itself well within the highly competitive drug manufacturing sector. Despite facing industry challenges, such as pricing pressures and regulatory changes, the company remains optimistic about growth trajectories moving forward, especially with newer product offerings in the pipeline.

Key Performance Indicators

Revenue
Increasing
15.70B
QoQ: 10.92% | YoY: 9.02%
Gross Profit
Increasing
9.32B
59.39% margin
QoQ: 15.82% | YoY: 105.20%
Operating Income
Increasing
2.65B
QoQ: 48.16% | YoY: 90.53%
Net Income
Increasing
1.63B
QoQ: 76.62% | YoY: 115.61%
EPS
Increasing
3.02
QoQ: 76.61% | YoY: 115.71%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q1 2026 15,695.70 3.02 +9.0% View
Q3 2024 14,150.50 1.71 +18.4% View
Q2 2024 12,237.00 0.37 -0.1% View
Q1 2024 11,949.10 0.23 +1.1% View
Q4 2023 13,809.00 1.91 +4.3% View